Product Description
Artesunate injection is used to treat severe malaria. This medicine is also used together with other medicines (eg, 8-aminoquinoline medicine) to treat severe malaria caused by Plasmodium ovale or Plasmodium vivax. (Sourced from: https://www.mayoclinic.org/drugs-supplements/artesunate-intravenous-route/side-effects/drg-20489625?p=1)
Mechanisms of Action: NOTCH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Belgium | Brazil | China | Colombia | Croatia | Czech | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | India | Indonesia | Ireland | Italy | Latvia | Lithuania | Malaysia | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Slovakia | Slovenia | South Africa | Sweden | Thailand | Ukraine | United Kingdom | United States | Vietnam
Approved Indications: Malaria | Malaria, Vivax
Known Adverse Events: Malaria | Hemoglobinuria
Company: Ministry of Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Congo, Kenya, Korea, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 2: COVID-19|Carcinoma in Situ|Cervical Cancer|Friedreich Ataxia|Malaria|Papillomavirus Infections|Squamous Cell Carcinoma|Squamous Intraepithelial Lesions of the Cervix|Uterine Cancer|Uterine Cervical Dysplasia|Vulvar Cancer|Vulvar Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ART-AIN IIB-2 | P2 |
Recruiting |
Squamous Cell Carcinoma|Squamous Intraepithelial Lesions of the Cervix|Papillomavirus Infections|Carcinoma in Situ |
2025-12-31 |
|
| LCCC2236 | P1 |
Recruiting |
Cervical Cancer|Uterine Cervical Dysplasia|Uterine Cancer |
2025-12-01 |
|
| ART-CIN_IIB | P2 |
Recruiting |
Uterine Cervical Dysplasia|Uterine Cancer|Papillomavirus Infections|Cervical Cancer |
2025-07-31 |
|
| anal HSIL HIV- | P2 |
Active, not recruiting |
Papillomavirus Infections|Squamous Intraepithelial Lesions of the Cervix|Carcinoma in Situ|Squamous Cell Carcinoma |
2024-12-28 |